ECOR electroCore, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1560258 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY27.2%
TTM net income YoY-17.5%
TTM EPS YoY-3.8%
Revenue 3-yr CAGR55.1%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-41.1%
Net margin-43.6%
FCF margin-25.8%
EBITDA margin-39.5%
Returns
ROE-478.7%
ROA-71.4%
ROIC (approx.)-1,217.4%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets109.2%
Debt / equity—
Current ratio1.38x
Interest coverage-882.75x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.69M | $9.45M | $9.58M | $9.24M | $8.69M | $7.38M | $6.72M | $7.05M |
| Cost of revenue | $1.12M | $1.27M | $1.22M | $1.07M | $1.22M | $939,000 | $1.01M | $994,000 |
| Gross profit | $8.57M | $8.18M | $8.36M | $8.17M | $7.47M | $6.44M | $5.71M | $6.05M |
| R&D expense | — | — | — | — | $662,000 | $511,000 | $642,000 | $805,000 |
| SG&A expense | $9.70M | $10.13M | $12.94M | $10.19M | $9.69M | $9.44M | $8.89M | $8.32M |
| Operating income | -$1.56M | -$2.77M | -$5.32M | -$2.94M | -$2.88M | -$3.51M | -$3.82M | -$3.07M |
| Interest expense | $3,700 | $3,300 | $4,000 | $2,100 | $3,300 | $4,500 | $5,000 | $5,400 |
| Pretax income | -$1.47M | -$3.06M | -$5.59M | -$2.98M | -$3.40M | -$3.67M | -$3.90M | -$3.20M |
| Income tax | -$126,000 | $0 | -$321,000 | $51,000 | $0 | $0 | -$48,000 | $29,000 |
| Net income | -$1.34M | -$3.06M | -$5.27M | -$3.04M | -$3.40M | -$3.67M | -$3.85M | -$3.23M |
| EBITDA | -$1.55M | -$2.77M | -$5.29M | -$2.83M | -$2.77M | -$3.38M | -$3.67M | -$2.90M |
| EPS (basic) | -0.13 | -0.33 | -0.59 | — | -0.40 | -0.44 | -0.47 | — |
| EPS (diluted) | -0.13 | -0.33 | -0.59 | — | -0.40 | -0.44 | -0.47 | — |
| Weighted avg. shares (diluted) | 9.95M | 9,404 | 8,953 | — | 8.45M | 8,316 | 8,289 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.31M | $8.50M | $4.85M | $7.04M | $7.86M | $3.37M | $3.78M | $3.70M |
| Short-term investments | $1.20M | $1.54M | $3.98M | $4.58M | $5.09M | $3.77M | $3.98M | $8.52M |
| Receivables | $1.62M | $909,000 | $872,000 | $1.03M | $1.48M | $813,000 | $1.46M | $1.37M |
| Inventory | $3.96M | $2.42M | $1.98M | $1.63M | $1.21M | $1.43M | $1.73M | $1.68M |
| Current assets | $14.45M | $14.12M | $12.53M | $15.67M | $17.35M | $10.56M | $11.97M | $16.30M |
| PP&E, net | $371,000 | $375,000 | $364,000 | $382,000 | $194,000 | $197,000 | $183,000 | $158,000 |
| Total assets | $17.26M | $17.06M | $15.48M | $18.67M | $21.41M | $14.56M | $16.04M | $20.47M |
| Current liabilities | $10.78M | $11.67M | $12.31M | $11.35M | $12.14M | $9.62M | $7.86M | $9.15M |
| Short-term debt | $313,000 | $1.00M | $250,000 | — | — | — | — | — |
| Long-term debt | $6.58M | $5.77M | $6.44M | $6.61M | $6.53M | — | — | — |
| Total debt | $6.89M | $6.77M | $6.69M | $6.61M | $6.53M | — | — | — |
| Total liabilities | $19.77M | $19.85M | $21.17M | $20.38M | $22.48M | $13.45M | $11.68M | $12.93M |
| Shareholders' equity | -$2.51M | -$2.79M | -$5.69M | -$1.71M | -$1.07M | $1.11M | $4.37M | $7.54M |
| Net debt | $589,000 | -$1.73M | $1.83M | -$428,000 | -$1.33M | — | — | — |
| Shares outstanding | 9.17M | 9.00M | 8.13M | 8.00M | 7.64M | 7.47M | 7.42M | 6.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.83M | -$3.52M | -$3.01M | -$1.54M | -$1.67M | -$623,000 | -$4.36M | -$1.25M |
| Capital expenditure | $0 | $4,000 | $2,000 | $0 | $4,000 | $25,000 | $37,000 | — |
| Free cash flow | -$2.83M | -$3.52M | -$3.01M | -$1.54M | -$1.67M | -$648,000 | -$4.39M | — |
| Investing cash flow | $348,000 | $2.43M | $597,000 | $518,000 | -$1.33M | $185,000 | $4.50M | -$501,000 |
| Financing cash flow | $288,000 | $4.74M | $230,000 | -$40,000 | $7.48M | $3,000 | $180,000 | $371,000 |
| Depreciation & amortization | $9,000 | $6,000 | $21,000 | $107,000 | $118,000 | $121,000 | $155,000 | $168,000 |
| Stock-based compensation | $617,000 | $755,000 | $1.04M | $470,000 | $415,000 | $505,000 | $540,000 | $514,000 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.